Antifungal Susceptibilities of Candida Species Causing Vulvovaginitis and Epidemiology of Recurrent Cases

ABSTRACT There are limited data regarding the antifungal susceptibility of yeast causing vulvovaginal candidiasis, since cultures are rarely performed. Susceptibility testing was performed on vaginal yeast isolates collected from January 1998 to March 2001 from 429 patients with suspected vulvovaginal candidiasis. The charts of 84 patients with multiple positive cultures were reviewed. The 593 yeast isolates were Candida albicans (n = 420), Candida glabrata (n = 112), Candida parapsilosis (n = 30), Candida krusei (n = 12), Saccharomyces cerevisiae ( n = 9), Candida tropicalis (n = 8), Candida lusitaniae (n = 1), and Trichosporon sp. (n = 1). Multiple species suggesting mixed infection were isolated from 27 cultures. Resistance to fluconazole and flucytosine was observed infrequently (3.7% and 3.0%); 16.2% of isolates were resistant to itraconazole (MIC ≥ 1 μg/ml). The four imidazoles (econazole, clotrimazole, miconazole, and ketoconazole) were active: 94.3 to 98.5% were susceptible at ≤1 μg/ml. Among different species, elevated fluconazole MICs (≥16 μg/ml) were only observed in C. glabrata (15.2% resistant [R], 51.8% susceptible-dose dependent [S-DD]), C. parapsilosis (3.3% S-DD), S. cerevisiae (11.1% S-DD), and C. krusei (50% S-DD, 41.7% R, considered intrinsically fluconazole resistant). Resistance to itraconazole was observed among C. glabrata (74.1%), C. krusei (58.3%), S. cerevisiae (55.6%), and C. parapsilosis (3.4%). Among 84 patients with recurrent episodes, non-albicans species were more common (42% versus 20%). A ≥4-fold rise in fluconazole MIC was observed in only one patient with C. parapsilosis. These results support the use of azoles for empirical therapy of uncomplicated candidal vulvovaginitis. Recurrent episodes are more often caused by non-albicans species, for which azole agents are less likely to be effective.

[1]  G. Quindós,et al.  In-vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole. , 1999, The Journal of antimicrobial chemotherapy.

[2]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[3]  M. Pfaller,et al.  Activities of Fluconazole and Voriconazole against 1,586 Recent Clinical Isolates of Candida Species Determined by Broth Microdilution, Disk Diffusion, and Etest Methods: Report from The ARTEMIS Global Antifungal Susceptibility Program, 2001 , 2003, Journal of Clinical Microbiology.

[4]  S. Zinner,et al.  The Incidence of Genitourinary Infections in a Cohort of Healthy Women , 1994, Sexually transmitted diseases.

[5]  P. Nyirjesy,et al.  Chronic fungal vaginitis: the value of cultures. , 1995, American journal of obstetrics and gynecology.

[6]  J. Sobel,et al.  Vaginitis due to Candida krusei: epidemiology, clinical aspects, and therapy. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  M. Pfaller,et al.  Role of Sentinel Surveillance of Candidemia: Trends in Species Distribution and Antifungal Susceptibility , 2002, Journal of Clinical Microbiology.

[8]  O. Lee,et al.  Vulvovaginal carriage of yeasts other than Candida albicans , 2003, Sexually transmitted infections.

[9]  J. Sobel,et al.  Immunopathogenesis of recurrent vulvovaginal candidiasis , 1996, Clinical microbiology reviews.

[10]  J. Sobel,et al.  Comparative in vitro activity of antimycotic agents against pathogenic vaginal yeast isolates. , 1994, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.

[11]  J. Sobel,et al.  Symptomatic vulvovaginitis due to fluconazole-resistant Candida albicans in a female who was not infected with human immunodeficiency virus. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  K. Holmes,et al.  Establishing the cause of genitourinary symptoms in women in a family practice. Comparison of clinical examination and comprehensive microbiology. , 1984, JAMA.

[13]  R. Dietze,et al.  Susceptibility profile of vaginal yeast isolates from Brazil , 2004, Mycopathologia.

[14]  R. Barton,et al.  An investigation into the pathogenesis of vulvo-vaginal candidosis , 2001, Sexually transmitted infections.

[15]  L. Dorrell,et al.  Vulvovaginitis due to fluconazole resistant Candida albicans following self treatment with non-prescribed triazoles , 2002, Sexually transmitted infections.

[16]  P. Marone,et al.  Prevalence of and risk factors for fungal vaginitis caused by non-albicans species. , 1997, American journal of obstetrics and gynecology.

[17]  M. Pfaller,et al.  Antifungal susceptibility of South African oral yeast isolates from HIV/AIDS patients and healthy individuals. , 2002, Diagnostic microbiology and infectious disease.

[18]  L. Riley,et al.  Prevalence of vaginal colonization by drug-resistant Candida species in college-age women with previous exposure to over-the-counter azole antifungals. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  J. Sobel,et al.  Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. , 2004, The New England journal of medicine.

[20]  M. Del Poeta,et al.  Prevalence and antifungal susceptibility of vaginal yeasts in outpatients attending a gynecological center in Ancona, Italy , 1997, European Journal of Epidemiology.

[21]  H. Nelis,et al.  Prevalence of Vulvovaginal Candidiasis and Susceptibility to Fluconazole in Women , 2003 .

[22]  Swate Te,et al.  Boric acid treatment of vulvovaginal candidiasis. , 1974 .

[23]  P. Nyirjesy,et al.  Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. , 1998, American journal of obstetrics and gynecology.

[24]  M. Brandt,et al.  Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. , 1999, Diagnostic microbiology and infectious disease.

[25]  J. Sobel,et al.  Treatment of Torulopsis glabrata vaginitis: retrospective review of boric acid therapy. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  Jack D Sobel,et al.  Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. , 2003, American journal of obstetrics and gynecology.

[27]  P. Nyirjesy,et al.  Fluconazole Susceptibility of Vaginal Isolates Obtained from Women with Complicated Candida Vaginitis: Clinical Implications , 2003, Antimicrobial Agents and Chemotherapy.

[28]  J. Rex,et al.  Has antifungal susceptibility testing come of age? , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  P. Nyirjesy,et al.  Over‐the‐Counter and Alternative Medicines in the Treatment of Chronic Vaginal Symptoms , 1997, Obstetrics and gynecology.

[30]  J. Sobel,et al.  Vaginitis due to Saccharomyces cerevisiae: epidemiology, clinical aspects, and therapy. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.